Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mediwound Ltd Ord Sh (NQ: MDWD ) 16.84 +0.02 (+0.09%) Streaming Delayed Price Updated: 2:38 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mediwound Ltd Ord Sh < Previous 1 2 3 4 5 Next > MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns August 15, 2024 Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages From MediWound Ltd. Via GlobeNewswire MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024 August 14, 2024 MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update August 14, 2024 From MediWound Ltd. Via GlobeNewswire Preview: MediWound's Earnings March 20, 2024 Via Benzinga Recap: MediWound Q3 Earnings November 21, 2023 Via Benzinga MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) August 05, 2024 NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients From MediWound Ltd. Via GlobeNewswire MediWound to Report Second Quarter 2024 Financial Results August 02, 2024 Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers July 29, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program July 16, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces $25 Million Strategic Private Placement Financing July 15, 2024 Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment From MediWound Ltd. Via GlobeNewswire Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session July 05, 2024 Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family Via Benzinga US Stocks Mixed; Jobs Figures Top Estimates For June July 05, 2024 Via Benzinga Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket July 05, 2024 Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million... Via Benzinga MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024 May 29, 2024 MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace MediWound Reports First Quarter 2024 Financial Results and Provides Company Update May 29, 2024 From MediWound Ltd. Via GlobeNewswire MediWound to Report First Quarter 2024 Financial Results May 22, 2024 Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences April 25, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session April 17, 2024 Via Investor Brand Network MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023 March 21, 2024 MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. Via InvestorPlace MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update March 21, 2024 From MediWound Ltd. Via GlobeNewswire Earnings Scheduled For March 21, 2024 March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Via Benzinga MediWound to Report Fourth Quarter and Full Year 2023 Financial Results March 14, 2024 Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time From MediWound Ltd. Via GlobeNewswire MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study February 12, 2024 Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... From MediWound Ltd. Via GlobeNewswire MediWound to Participate in Two Upcoming Investor Conferences February 05, 2024 From MediWound Ltd. Via GlobeNewswire MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns January 09, 2024 From MediWound Ltd. Via GlobeNewswire Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development December 28, 2023 Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S. Via Benzinga MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army December 28, 2023 Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million From MediWound Ltd. Via GlobeNewswire MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads December 21, 2023 Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement From MediWound Ltd. Via GlobeNewswire Earnings Scheduled For November 21, 2023 November 21, 2023 Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million. Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
